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Introduction 
Transdermal delivery of drugs through the skin to the 
systemic  circulation  provide  a  convenient  route  of 
administration to the  delivery of  drugs for  prolonged 
therapy  in  diseases  like  hypertension  and  diabetes.
1 
Cardiovascular diseases account for a large proportion 
of all deaths and disability worldwide. Global Burden 
of Disease study reported that in 1990 there were 5.2 
million  deaths  from  cardiovascular  diseases  in 
economically  developed  countries  and  9.1  million 
deaths from the same causes in developing countries.
2,3 
Worldwide  frequency  estimates  for  hypertension  may 
be as much as 1 billion individuals, and approximately 
7.1  million  deaths  per  year  may  be  attributable  to 
hypertension.
4 
There  are  many  oral  drugs  used  in  the  treatment  of 
hypertension.  However  problem  may  arise  with  oral 
delivery due to uneven bio-distribution throughout the 
body, a lack of drug targeting specificity, the necessity 
of a large dose to achieve high blood concentration and 
adverse side effects due to such high doses. It is also 
noted that difficulties in the treatment of hypertension 
does  not  necessarily  lie  in  the  inadequacies 
pharmacological therapeutics but it may be due to poor 
patient  compliances  during  lifelong  administration. 
Approximate  50  %  of  hypertensive  patients  do  not 
fulfill  with  their  prescribed  treatment.
5  Reason 
suggested  for  this  complication  includes  intolerable 
side effects, complex treatment and lake of reminders.
5 
Lisinopril  is  an  angiotensin-converting  enzyme 
inhibitor used for the treatment of hypertension. It is 
available only in the form of oral tablets in the market 
with  slow  and  incomplete  absorption  after  oral 
administration  with  a  bioavailability  of  25–30%.
6-7 
Lisinopril is an ideal candidate for transdermal study 
because of low oral dose (2.5–20 mg), low molecular 
mass (405.5 g/mol), and low oral bioavailability (25%). 
This study investigated the iontophoretic permeability 
of  lisinopril  through  excised  pig  skin  to  assess  its 
potential  for  the  development  of  a  patient-controlled 
active transdermal system.  
The  first  commercial  patch  was  approved  for 
scopolamine in 1979. Some other available transdermal 
patches  in  world  drug  market  are:  nitroglycerin, 
nicotin,  clonidine,  fentanyl,  estradiol,  testosterone, 
lidocain, and oxbutinin. Skin has been recognized as a 
route  of  drug  administration  for  decades  but  limited 
permeability  of  human  skin  is  still  a  basic  problem, 
restraining its widespread therapeutic use also limiting 
suitability of number of drug candidates for this route. 
So  it  is  the  very  big  challenge  of  creating  effective 
transdermal system because it involves adequate drug 
permeability  through  the  stratum  corneum.
8 
Introduction  of  the  physical  enhancement  techniques 
like  iontophoresis  combined  with  the  prospect  of  the 
programmed  delivery  has  contributed  significantly  in 
the  expansion  of  transdermal  research.  Iontophoresis 
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may be defined as facilitated movement of compounds, 
in particular charged moiety, into or across a membrane 
by  the  application  of  an  externally  applied  electrical 
potential  difference  across  the  membrane.
9 
Iontophoresis  has  provided  a  non-invasive  delivery 
system for local or systemic delivery of drugs. Beside 
the  common  benefit  of  transdermal  delivery 
iontophoresis presents a unique opportunity to provide 
programmed  drug  delivery.
10  The  enhancement  of 
permeation by the iontophoresis results from a possible 
mechanism including electro-osmosis, electro repulsion 
or  current  induced.
11,12  Iontophoretic  products  have 
already  been  launched  in  the  US  market  and  gained 
growing acceptance for the topical delivery of drugs
13,14 
hence  attempts  have  been  undertaken  to  develop 
transdermal iontophoretic system for lisinopril.  
Materials and Methods 
Lisinopril  was  a  gift  sample  from  Lupin  laboratories 
Bhopal. Silver plates (purity 99.99%, 5 mm diameters) 
were  obtained  from  a  goldsmith  shop  Bhopal,  India. 
Sodium Chloride AR, octanol, isopropyl alcohol, silver 
chloride were obtained from SD Fine-Chem (Mumbai, 
India).  Franz-diffusion  cell  was  designed  by  Peekay 
scientific  glass  wares,  Bhopal,  All  the 
reagents/chemicals  used  were  of  analytical  grade. 
Experiments  were  conducted  with  ultra  pure  water 
(resistivity,  18.2  MW  cm)  obtained  from  Milli-Q 
Academic System. 
Equipment 
Iontophoretic DC source (digital display, current 0-10 
mA, voltage 0-25 V) was purchased from C-tech Psu-
2510/lab (Mumbai, India) and iontophoretic diffusion 
cell was fabricated by Navin Scientific Glass Product 
(Bangalore,  India)  as  per  given  specifications. 
Silver/silver chloride electrode was prepared as per the 
standard  procedure.
14  Silver  wire  (99.99%  pure,  1.0 
mm  thickness)  was  used  as  connecting  wire.  U-V 
Visible  Spectrophotometer-  Shimadzu  UV-1700  PC 
Shimadzu Corporation, Japan was used for analysis.  
Experimental Design 
Iontophoretic  transdermal  permeation  study  of 
Lisinopril  was  carried  out  at  different  concentrations 
and  current  densities.  Different  systems  having 
different  concentration  (current  density  0.5  mA/cm
2) 
had been designed as System A, System B, System C 
having  concentration  25  mg/ml,  50  mg/ml  and  75 
mg/ml  respectively.  Moreover  system  with  different 
current densities (concentration 25 mg/ml) designed as 
System  A1,  System  A2,  SystemA3  having  current 
densities 0.25, 0.5 and 0.75 mA/cm
2 respectively. 
Preparation of skin membrane 
From  a  local  abattoir,  ear  was  obtained  from  freshly 
slaughtered pigs. The skin was removed carefully from 
the  outer  regions  of  the  ear  and  separated  from  the 
underlying cartilage with a scalpel. After separating the 
full thickness skin, the fat adhering to the dermis side 
was  removed  using  a  scalpel  and  isopropyl  alcohol. 
Finally the skin was washed with tap water and stored 
at refrigerator in aluminum foil packing and was used 
within two days.
15 
 
In vitro passive permeation studies 
The in vitro passive permeation studies were performed 
using  vertical  type  Franz  diffusion  cell  having  a 
receptor compartment capacity of 10 ml. The excised 
skin  was  mounted  between  the  half-cells  with  the 
dermis in contact with receptor fluid (Phosphate buffer 
pH 7.4) and equilibrated for 1 h. The area available for 
diffusion  was  about  1.21cm
2.  The  donor  cell  was 
covered  with  an  aluminum  foil  to  prevent  the 
evaporation  of  vehicle.  The  fluid  in  the  receptor 
compartment  was  maintained  at  37±0.5  °C.  Under 
these  conditions,  the  temperature  at  the  skin  surface 
was  approximately  32  °C.  Different  solution  of 
lisinopril in phosphate buffer pH 7.4 (each one ml) was 
placed in the donor compartment. The entire assembly 
was kept on a magnetic stirrer and the solution in the 
receiver compartment was stirred continuously using a 
magnetic  bead.  The  sample  solution  was  withdrawn 
from the receptor compartment at regular intervals and 
assayed for drug content.
16 
 
Procedure of iontophoretic diffusion 
For the iontophoretic study, diffusion cell was modified 
according to Glikfield et al.
17 The apparatus essentially 
consisted  of  a  glass  molded  large  receiving  chamber 
provided with two parallel ports on the topside and a 
sampling  port  on  the  side.  Two  upper  chambers  are 
made  from  open-ended  cylindrical  glass  tubes,  the 
outer diameters of which were equivalent to the inner 
diameter  of  the  parallel  ports.  The  lower  10  mm  of 
these  tubes  were  slightly  constricted  to  allow  a 
clearance of 1 to 1.5 mm on the side. This ensured easy 
fitting. After the skin was tied at this constricted end, 
the  effective  diameter  increased  and  became  exactly 
equal  to  inner  diameter  of  the  extended  ports.  Once 
slipped into parallel ports, they stay attached by glass 
joints forming two separate chambers with skin at the 
base. Both the skin touched the receptor solution at the 
same  depth  and  each  chamber  housed  one  electrode. 
Once  the  battery  was  switched  on,  current  flowed 
through  the  skin  placed  in  anodal  compartment  into 
receiving  solution  below  and  reached  the  cathodal 
electrode through the skin tied to cathodal end. Donor 
solution  was  filled  in  one  of  the  top  chambers 
depending  on  the  polarity  of  the  drug  and  the  other 
serve  as  return  electrode  chamber.  For  our  study, 
silver/silver  chloride  electrode  was  inserted  into  the 
donor  compartment  whereas  silver  plate  was  inserted 
into anodal chamber as return electrode. Direct current 
(0.25-0.75 mA cm
-2) was used throughout experiment. 
The  receptor  fluid  (5  ml)  was  withdrawn  at  regular 
intervals  and  replaced  with  fresh  buffer  to  maintain 
sink  condition.  Samples  were  assayed  by  the  U-V 
spectrophotometrically.   
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Solubility determination 
Excess amounts of drug were taken into glass vials and 
dissolved in  measured  amount  of  different  solvent  to 
get saturated solutions. The solutions were kept at rest 
for 24 h to assist the attainment of equilibrium with the 
undissolved  drug  particles.  From  these  solutions,  the 
supernatant  was  filtered  to  separate  the  undissolved 
drug  particles  and  diluted  suitably  and  the 
concentrations were measured.
18 
 
Partition coefficient 
The octanol / phosphate buffer partition coefficient of 
the lisinopril was determined by shaking equal volume 
of octanol and phosphate buffer in a separating funnel 
for 10 min and allowing  to stand for 24 h.  Aqueous 
phase was assayed before and after partitioning to get 
the  partition  coefficients.
18,19  Skin/vehicle  partition 
coefficient  was  determined  by  dipping  the  skin  in 
known concentrations of drug in phosphate buffer for 
24  h,  assaying  aqueous  phase  remaining  drug  for 
estimation of concentration after partitioning. 
 
Data analysis 
The cumulative amount permeated was plotted against 
time, and the slope of the linear portion of the plot was 
estimated  as  the  steady  state  flux.  Permeability 
coefficient  and  diffusion  coefficient  were  calculated 
using following formulas
20:
 
KP = JSS / Cd ……………. (1) 
D = KP h / K …….……….. (2) 
where Kp represents permeability coefficient, Jss is the 
steady-state  flux,  Cd  is  the  concentration  of  drug  in 
donor compartment, D is the diffusion coefficient, K is 
the skin/vehicle partition coefficient and h the thickness 
of  the  skin.  Flux  enhancement  was  calculated  by 
dividing  iontophoretic  steady  state  flux  by  the 
corresponding passive steady state flux. 
 
Statistical analysis 
Statistical  analysis  was  carried  out  using  2-  way 
ANOVA. The effect of  concentration on steady  state 
flux  was  separately  evaluated  by  one-way  ANOVA 
followed  by  Bonferroni’s  test.
21  At  95%  confidence 
intervals, p values less than 0.05 were considered to be 
significant. 
 
Results and Discussion 
Permeability  of  drug  through  skin  is  strongly 
influenced  by  its  physicochemical  parameters. 
Molecular  weight  for  ideal  candidate  of  transdermal 
drug  delivery  suggested  around  200-500  Da  by  Doh 
and  co-workers.
22  Lisinopril  having  molecular  weight 
405.5  fits  into  this  category.  Physicochemical 
parameters  of  lisinopril  were  investigated  and  the 
results were listed in Table 1. The drug showed good 
solubility  in  water  (90.47  mg/ml).  Phosphate  buffer 
(pH 7.4) was used as receiver fluid in our study, by this 
basis saturation solubility was also determined in this 
media. Solubility of Lisinopril in phosphate buffer (pH 
7.4)  was  found  90.68  mg/ml  which  is  very  close  to 
solubility  of  Lisinopril  in  water.  The  octanol–water 
partition  coeﬃcient  is  a  measure  of  the  relative 
lipophilicity  of  a  compound.  The  experimentally 
determined  partition  coeﬃcient  (octanol/phosphate 
buffer pH 7.4) was found to be 0.675 ± 0.0124, which 
indicated  that  the  drug  had  less  affinity  towards  the 
lipids  compared  to  phosphate  buﬀer.  However,  the 
lipophilicity of a drug moiety is an intrinsic character 
and cannot be changed. 
At pH 7.4 mammalian skins are negatively charged and 
ionic forms have low affinity toward skin. Lisinopril, 
being an acidic drug with the pKa value of 3.85, was 
largely  ionized  which  reduced  its  affinity  toward  the 
skin.
23  In  iontophoresis,  the  ionized  moieties  actively 
propelled through natural pore pathways of skin while 
the unionized fraction could pass the unbroken horny 
layers  by  passive  permeation  resulting  in  enhanced 
permeation.
24 To simulate the physiological condition, 
the  diffusion  cell  was  modified  where  both  the 
electrodes  were  place  on  the  same  side  of  skin.  The 
receiving chamber with phosphate buffer reflected the 
body.  The  permeability  and  diffusion  parameters  are 
very important for comparison purpose.
25 It is evident 
that  as  the  concentrations  increases  in  donor  the 
permeability  coefficients  decrease.  Result  for  the 
permeability and diffusion coefficients of lisinopril in 
different systems in our study for passive diffusion and 
iontophoresis are provided in Table 2, which found to 
be obey above hypothesis.  
 
Table 1. Physicochemical Parameters of Lisinopril 
 
Trial No. 
Solubility (mg/ml)  Partition Coefficient 
Octanol/Phosphate Buffer 7.4 pH 
Molecular Weight 
(g/mol)  Phosphate buffer 7.4 pH  Water 
1  90.12  93.22  0.671 
405.5 
2  92.14  90.87  0.689 
3  89.78  87.34  0.665 
Mean±SD  90.68±1.2757  90.47±2.9596  0.675±0.0124  
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Table 2. Comparison of Permeation & Diffusion coefficients of Lisinopril in different Systems by Passive and Iontophoresis 
Donor System 
Permeability Coefficient (cm/hr)  Diffusion coefficient (cm
2/s) 
Passive  Iontophoretic  Passive  Iontophoretic 
System- A  0.0252  0.0797  0.1147* 10
-5  0.3629* 10
-5 
System-B  0.0250  0.0789  0.1138* 10
-5  0.359* 10
-5 
System-C  0.0235  0.0543  0.1070* 10
-5  0.247* 10
-5 
 
Among  the  various  factors  that  affect  passive 
permeability,  the  concentration  of  the  actives  in  the 
donor system is most crucial. To evaluate this effect, 
the  experiment  was  design  at  three  different  drug 
concentrations. Results show that overall iontophoretic 
permeability  at  all  concentration  level  significantly 
higher  that  of  passive  values.  The  passive  and 
iontophoretic  permeation  profiles  of  lisinopril  at 
different donor concentrations are shown in Figures 1 
and  2.  The  passive  profiles  are  linear  at  all 
concentration levels indicating the permeation kinetics 
was  more  or  less  zero  order.  In  the  passive  process, 
both the rate and extent of permeation increased with 
increasing  donor  drug  concentrations.  This  was 
expected as  increase  in the  donor  drug  concentration 
enhanced  the  concentration  gradient,  which  was  the 
driving  force  of  mass  transport.
26  In  contrasts 
iontophoretic  profiles  were  less  linear  indicating  the 
involvement  of  multitude  of  factors.  When  the 
concentration of the drug was raised from low (System 
A)  to  medium  (System  B),  the  permeation  rate 
increased but there no significant increase was found at 
the highest concentration (System C) over that of next 
lower  concentration.  This  was  in  agreement  with  the 
hypothesis  that  in  the  drug  concentration  increases 
iontophoretic delivery upto a certain point, but at still 
higher  concentrations,  the  flux  may  become 
independent of concentration.
27 In iontophoresis though 
ionic repulsion is the dominant force, convective flow 
of  solutes  toward  the  direction  of  current,  influences 
the permeation rate. Permeability of skin also changes 
under influences of current.
28 
The total ﬂux  of a solute  during iontophoresis is  the 
sum of ﬂuxes due to electro-repulsion, convective flow, 
and passive diffusion.
24 Lisinopril (pKa 3.85) at pH 7.4 
acquires  a  negative  charge  and  was  delivered  from 
cathodal  chamber.  Since  the  isoelectric  point  of  the 
skin varies between 3 and 4, at physiological pH, the 
volume ﬂow was directed toward the cathode. Hence at 
pH 7.4, only passive and electro-repulsive ﬂuxes were 
likely to contribute to the overall permeation. Electro-
osmotic ﬂow may even oppose the permeation from the 
cathodal  compartment.
29  The  iontophoretic  profile 
showed  the  initial  permeation  was  high  but  the 
permeation rate declined in the later hours. This was 
unexpected as the voltage gradually dropped with time 
and hence the magnitude of electro-osmotic opposition 
was expected to be lesser in the later part of the study. 
The  opposite  result  suggested  the  involvement  of  a 
factor that negatively inﬂuenced the permeation as time 
progressed.  It  is  possible  that  during  the  passage  of 
current,  the  cathodal  electrode  (Ag/AgCl)  received  a 
steady ﬂow of electron, which resulted in the liberation 
of  negatively  charged  chloride  ions.  As  time 
progressed,  the  concentration  of  this  newly  released 
chloride  ions  were  likely  to  increase  in  the  cathodal 
compartment. Since the drug was negatively charged, 
chloride  ions  served  as  competitor.  A  chloride  ion, 
being much smaller than the drug ion, was a powerful 
competitor, which  reduced the  transport efficiency  of 
lisinopril.
30 
 
 
 
Figure  1.  Permeation  profile  of  Lisinopril  (Iontophoresis) 
at different donor concentrations (n=3). 
 
 
 
Figure  2.  Permeation  profile  of  Lisinopril  (passive)  at 
different donor concentrations (n=3). 
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Table 3 depicts the enhancement in iontophoretic flux 
compared  to  the  passive  flux  of  same  donor 
concentration. Enhanced permeation was highest at the 
lowest drug load and lowest at the highest drug load. 
The iontophoretic contribution was found to be slightly 
more at higher donor concentrations. 
 
Table 3. Enhancement Ratio and Benefit by iontophoresis 
Donor Systems 
Steady State flux (g/ hr.cm2)  Benefit by Iontophoresis 
(g/hr.cm2) 
Enhancement 
Ratio (R)  Passive  Iontophoretic 
System-A  1.429  4.517  3.088  3.160 
System-B  2.841  8.636  5.795  3.0397 
System-C  3.998  9.227  5.229  2.3079 
 
The  effect  of  current  densities  on  the  transport  of 
lisinopril through pig ear skin, experiment was carried 
out at three different current densities and result was 
found  that  iontophoretic  drug  transport  of  lisinopril 
increased with the increasing current densities. (Figure 
3).  
 
 
Figure  3.  Permeation  Profile  of  Lisinopril  (Iontophoretic)  at 
different Current Densities (n=3).  
 
The  relationship  between  current  density  and  flux  of 
lisinopril may be described by Faraday’s law which is 
represent by following equation
31    
Ji = ti It / Zi F 
where  Ji,  Zi  are  the  flux  and  charge  of  lisinopril  at 
particular pH, It is the applied current density, F is the 
Faraday's constant, ti is a proportionality constant. 
Since  in  the  experimental  conditions  ti  and  Zi  i.e., 
charge of the drug was kept constant, then by above 
equation  flux  is  directly  proportional  to  the  current 
density. 
Literature  survey  suggested  that  disordering  of 
intracellular lipid of stratum corneum by increasing of 
current density may cause increase in drug transport.
32 
Some  researchers  suggested  that  possibility  may  be 
also that the electro-osmotic volume flow increase with 
an  increase  an  current  densities
33  which  leads  to 
increase in the flux of the drug.  
Experimental data indicate that by proper selection of 
donor solution current density and some other related 
factors, extent of lisinopril transport across skin can be 
manipulated.  
 
Conclusion  
The  present  work  shows  that  the  iontophoretic 
approach was feasible to enhance and control the rate 
of transdermal drug delivery of lisinopril. Study show 
that  iontophoretic  drug  delivery  increase  with  the 
current  densities  and  concentration,  but  in  case  of 
concentration permeation increase up to certain points, 
afterwards  flux  may  become  independent  of 
concentration.  It  can  be  said  that  lisinopril  is  a 
promising  candidate  for  transdermal  delivery  and  its 
delivery can be manipulates, controlled and optimized 
by iontophoresis.  
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